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 Abstract: 
Non-visual arrestins interact with hundreds of different G protein-coupled receptors 
(GPCRs). Here we show that by introducing mutations into elements that directly bind 
receptors, the specificity of arrestin-3 can be altered. Several mutations in the two parts of 
the central “crest” of the arrestin molecule, middle-loop and C-loop, enhanced or reduced 
arrestin-3 interactions with several GPCRs in receptor subtype and functional state-specific 
manner. For example, the Lys139Ile substitution in the middle-loop dramatically enhanced 
the binding to inactive M2 muscarinic receptor, so that agonist activation of the M2 did not 
further increase arrestin-3 binding. The Lys139Ile mutation made arrestin-3 essentially an 
activation-independent binding partner of M2, whereas its interactions with other receptors, 
including the 2-adrenergic receptor and the D1 and D2 dopamine receptors, retained normal 
activation dependence. In contrast, the Ala248Val mutation enhanced agonist-induced 
arrestin-3 binding to the 2-adrenergic and D2 dopamine receptors, while reducing its 
interaction with the D1 dopamine receptor. These mutations represent the first example of 
altering arrestin specificity via enhancement of the arrestin-receptor interactions rather than 
selective reduction of the binding to certain subtypes.  
 
1.Introduction 
 
Dysfunction of G protein-coupled receptor (GPCR) signaling plays an important role 
in the pathogenesis of numerous human diseases [1, 2]. Because receptor activity is crucial 
for normal cell function, it is tightly controlled by several regulatory mechanisms, with 
inappropriate activity linked with many disease states. For example, gain-of-function 
mutations that result in excessive activity or elevated ligand production that over-stimulates 
normal receptors can each cause endocrinological disorders and malignant tumors [1, 3, 4]. 
Conceivably, the introduction of negative regulators into pathological cells can suppress 
excessive signaling and potentially correct these problems.  
Arrestins bind active phosphorylated GPCRs [5, 6], thereby terminating G protein 
signaling [7], and facilitating receptor internalization [8]. Thus, arrestins can potentially be 
used in compensational therapy aiming at suppression of excessive G protein-mediated 
signaling [9, 10]. Vertebrates have more than 800 GPCRs [11, 12] and only four different 
arrestins [13]. Arrestin-1 and -4 are expressed in the visual system [14], whereas arrestin-2 
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and -3 (also known as β-arrestin1 and 2) are ubiquitously expressed, and each regulates 
hundreds of receptors. Previous work established that arrestins can be “pre-activated” by 
mutations destabilizing their basal conformation, thereby increasing their binding to GPCRs 
[15-17]. Enhanced arrestin-1 was shown to partially compensate for defects of rhodopsin 
phosphorylation in vivo [10]. Similarly, enhanced non-visual arrestins could reduce the 
signaling of hyperactive GPCRs. But as arrestin-2 and -3 are fairly promiscuous [18], 
enhanced non-visual arrestins would likely have unwanted side effects as they would 
simultaneously affect the function of all receptors expressed in the same cell. Thus, to use 
enhanced non-visual arrestins as therapeutic agents, their specificity must be dramatically 
increased.  
to the feasibility of engineering arrestin-2 and -3 with enhanced receptor selectivity is 
suggested by strict selectivity of visual arrestin-1, exclusively expressed in photoreceptor 
cells, for photopigments. Arrestin-1 binds to phosphorylated light-activated (P-Rh*) rhodopsin 
with much higher affinity than other receptors [19, 20]. Earlier studies identified elements [20] 
and individual residues on the receptor-binding surface [21] responsible for receptor 
preference of arrestins. The exchange of ten non-identical residues on the receptor-binding 
surface can change arrestin-1 preference to that of arrestin-2, and vice versa [21]. Point 
mutations at these positions were shown to increase of the preference of arrestin-3 for some  
cognate receptors over other up to 4-fold, whereas double mutations yielded 50-fold 
differential in the binding to M2 muscarinic over 2-adrenergic receptor [22]. Comparison of 
crystal structures [23, 24] and primary sequences of arrestin-1 and -2 additionally identifies a 
key valine residue in arrestin-1 that stabilizes its N-domain, and likely contributes to its high 
selectivity for rhodopsin, as demonstrated by a dramatic increase in the binding to non-
cognate M2 muscarinic receptor of arrestin-1 with a single Val83Ser mutation [23]. However, 
mutations of the ten “receptor-discriminator” residues identified in the arrestin-1/arrestin-2 
chimeras did not affect arrestin-3 binding to some of the GPCRs tested, including the D1 
dopamine [22] or Y1 neuropeptide [25] receptors, while some of the same mutations 
dramatically change arrestin-3 binding to D2 dopamine and Y2 neuropeptide receptors . Here 
we took advantage of the recent crystal structure of arrestin-1 in complex with rhodopsin [26], 
which identified additional elements, including the middle-loop and C-loop, both of which 
engage the receptor and therefore might play a role in arrestin selectivity. We used four 
model GPCRs (M2 muscarinic, 2-adrenergic, D1 dopaminergic, and D2 dopaminergic) and 
show that mutations in these regions of arrestin-3 differentially affect its basal and agonist-
induced binding.  
 
2. Material and methods 
   
2.1. Materials. 
Restriction endonucleases and other DNA modifying enzymes were from New England 
Biolabs (Ipswich, MA). Cell culture reagents and media were from Mediatech-Corning 
(Manassas, VA), Life-technologies (Carlsbad, CA), or PAA Laboratories GmbH (Pasching, 
Austria). Luciferase substrate coelenterazine h was from NanoLight Technology (Pinetop, 
AZ). DNA purification kits were from Zymo Research (Irvine, CA). All other reagents were 
from Amresco (Solon, OH) or Sigma-Aldrich (St Louis, MO). 
 
2.2. Mutagenesis and plasmid construction. 
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Plasmids encoding short splice variant of bovine arrestin-3 [27] with unique restriction sites 
introduced by silent mutations were used to introduce mutations on the background of 
Ala87Val base mutant (which is expected to be predisposed to higher receptor selectivity), as 
described [22, 25]. To generate all mutants, oligonucleotides harboring the desired 
substitutions were used as forward primers and an oligonucleotide downstream from the far 
restriction site was used as a reverse primer for PCR. Resulting fragments of various lengths 
and an appropriate primer upstream of the near restriction site were then used as reverse 
and forward primers, respectively, for the second round of PCR. Restriction sites BamHI and 
BsiWI were used for introducing indicated Lys139 substitutions and BsiWI and XbaI to 
introduce mutations in the C-domain. The resulting fragments were purified, digested with the 
respective enzymes, and subcloned into the suitably digested pGEM-2 plasmid (Promega; 
Madison, WI) encoding (WT) bovine arrestin-3 with engineered restriction sites [22]. 
     
2.3. Direct in vitro Binding Assay 
In vitro transcription, translation, preparation of light-activated phosphorylated rhodopsin (P-
Rh*), and in vitro direct binding assay were performed as previously described [21, 28].  
 
2.4. Bioluminescence Resonance Energy Transfer (BRET) Assay 
COS-7 cells were transfected using Lipofectamine 2000 (2μl Lipofectamine/1μg DNA) in 6 
well plates. We have previously determined the amounts of plasmid DNA to produce 
sufficient excess of arrestin-3 over receptor and therefore saturate the BRET signal [22, 29]. 
48 hours after transfection, the appropriate ligands (agonist carbachol (carbamoylcholine) 
and inverse agonist atropine for M2R, agonists isoproterenol for β2AR, dopamine for D1R, 
and quinpirole for D2R) were used at 10 μM. After stimulation, 5 μM luciferase substrate 
coelenterazine h was added, and BRET was measured between RLuc8-tagged receptors, 
and Venus-tagged arrestins, as previously described [22, 25, 29]. BRET measurements for 
Figure 5 were performed with Varioskan Flash Multimode Reader (Thermo Scientific, 
Waltham, MA).  
 
2.5. Co-immunoprecipitation 
HEK293 arrestin-2/3 KO cells [30] were co-transfected with HA-M2R-RLuc8 (0.5 µg) and a 
Venus-Arrestin construct (0.25-1 µg) using Trans-Hi™ DNA transfection reagent (1 µg DNA: 
3 µL reagent) in 6-well plates. At 48 hours post-transfection, the cells were incubated in 
either serum-free DMEM or serum-free DMEM with 10 µM carbachol (carbamoylcholine) for 
15 min. After stimulation, the cells were lysed in IP buffer (50 mM Tris-HCl pH 7.5, 2 mM 
EDTA, 250 mM NaCl, 10% glycerol, 0.5% NP-40, 20 mM NaF, and 1mM NaVO3) and 
incubated at 4°C for 1 h. The lysates were then centrifuged (max speed, 15 min) and the 
supernatants were pre-cleared by incubation for 1 h with 25 µL protein G agarose beads. 
The beads were pelleted by centrifugation, a 30 µL aliquot was removed for input analysis, 
and the remaining lysates were incubated overnight at 4°C with 1 µg HA antibody (Sigma-
Aldrich, 3F10). The next morning 50 µL protein G agarose beads were added and incubated 
for an additional 2 h. The beads were then washed three times with 1 mL of ice-cold IP buffer 
before elution with 35 µL of SDS sample buffer (Sigma-Aldrich, Laemmli 2X) at room 
temperature. Samples were analyzed by Western blot. Co-immunoprecipitated arrestins 
were quantified on blots using the QuantityOne Software (BioRad). The results from three 
 4 
independent experiments were statistically analyzed using one-way ANOVA followed by 
Dunnett’s post-hoc test (p<0.05 was considered significant).  
 
2.6. Data Analysis and Statistics 
GraphPad Prism 5.0 was used to plot the results of BRET experiments (Figs. 2-3), direct 
binding assay (Fig. 4), and to statistically analyze them, as described [22]. Protein 
sequences for multiple sequence alignments were taken from OMA database [31]. To 
characterize the level of residue conservation, entropy was calculated for each amino acid 
position.   
 
3. Results 
 
3.1. Highly conserved lysine residue in the middle-loop differentially effects basal receptor 
binding. 
All four vertebrate arrestins exhibit remarkable conservation of their structures, 
consisting of two “cup-like” domains [23, 24, 32-35] (Fig. 1A). Within this context, the 
receptor-binding surface of arrestins comprises the concave sides of both the N- and the C-
domains, as well as the central loops [21, 36-40]. The “middle-loop” [41], also called “139-
loop” in arrestin-1 [42, 43], is a flexible region, connecting β-strands VIII and IX in the N-
domain, forming part of the central crest on the receptor interaction surface (Fig. 1A, blue). It 
has been reported that the middle-loop plays an important role in the high selectivity of visual 
arrestin-1 for P-Rh* [42, 44], but its functional role in non-visual arrestins has not been 
reported in the literature. 
Multiple sequence alignment of the middle-loop region shows that lysine139 (in 
bovine arrestin-3) is highly conserved among all four arrestin subtypes in vertebrates (Fig. 
1B). However, various residues (Ile, Ala, Asp, Gln, Arg) are found in invertebrate arrestins in 
position homologous to Lys139 in arrestin-3 (Fig. 1B; see also [13]). Available structures 
suggest that a putative salt bridge involving this conserved lysine anchors the middle-loop to 
the receptor-binding “finger-loop” in the basal state of vertebrate arrestins [24, 44]. To test 
the role of lysine139 in arrestin-3, we substituted it with residues found in the equivalent 
position in non-vertebrate species. The wide variety of homologues provides interesting 
substitutions: uncharged (Gln, Ile, Ala), acidic (Asp), and other positively charged (Arg) 
residues have all appeared at the corresponding position during evolution, among which Ile 
and Ala represent the least conservative substitutions according to substitution matrices [45]. 
To measure arrestin interactions with GPCRs co-expressed in the same cell, we used 
bioluminescence resonance energy transfer (BRET) between receptors C-terminally tagged 
with Renilla luciferase and arrestins N-terminally tagged with Venus, as described [9, 22, 25, 
29]. The middle-loop mutations were introduced in arrestin-3 carrying an Ala87Val mutation, 
which is found in the corresponding position of arrestin-1. This Val residue is involved in 
multiple hydrophobic interactions in arrestin-1, and thus responsible for the rigidity of the N-
domain, which is proposed to ensure selective rhodopsin binding. The rationale for using the 
Ala87Val mutation in these studies is that it could predispose arrestin-3 to higher receptor 
selectivity, by making its N-domain less flexible. As a negative control, we used the arrestin-
3-KNC mutant, in which 12 key receptor-binding residues are replaced with alanines. 
Arrestin-3-KNC does not demonstrate basal or agonist-induced binding to any GPCR tested 
so far [22, 25, 29]. It is the most appropriate control for bystander BRET, as it has the same 
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molecular weight and therefore is expected to diffuse at the same rate as other arrestin-3 
variants.  
We tested several Class A GPCRs: 2-adrenergic (2AR), D1 (D1R) and D2 (D2R) 
dopamine, and M2 muscarinic (M2R) receptors. In the case of visual arrestin-1, certain 
mutations in the middle-loop “loosened up” the basal state of the molecule and facilitated 
arrestin-1 binding to P-Rh* and non-preferred forms of rhodopsin, light-activated 
unphosphorylated (Rh*) and inactive phosphorylated (P-Rh) [44, 46]. Therefore, we first 
investigated possible “pre-docking” of the arrestin-3 middle-loop mutants to the receptors 
without agonist stimulation (Fig. 2A). In the case of 2AR, Lys139 substitutions did not 
significantly affect basal arrestin binding, whereas we observed receptor-specific changes 
with the other three GPCRs. The most dramatic were the effects of Lys139Ile substitution, 
which increased pre-docking to M2R more than 3-fold, while decreasing basal interactions 
with D1R and D2R (Fig. 2A). Interestingly, while none of the other Lys139 substitutions 
affected basal binding of arrestin-3 to M2R, D2R, or 2AR, most of them reduced basal 
binding to D1R to varying degrees (Fig. 2A).  
The effects of Lys139 substitutions on agonist-induced binding to the tested receptors 
were remarkably different. The Lys139Ile mutation, which greatly increased the binding to 
inactive M2, essentially eliminated agonist-induced increase in binding to this receptor (Fig. 
2B). Apparently, the interaction between basal M2R and arrestin3-Lys139Ile mutant reached 
the maximum possible extent, so that the presence of M2 agonist could not further increase 
binding. None of the other Lys139 substitutions appreciably affected agonist-induced 
increase of M2 interaction. The conservative Lys139Arg substitution enhanced agonist-
induced binding to the 2-adrenergic receptor, whereas other mutations did not significantly 
affect it. The interactions with activated D1R were not perturbed by Lys139 substitutions, 
whereas the effect of D2R agonist quinpirole was reduced by the Lys139Ile mutation (Fig. 
2B).  
 3.2. The effects of the perturbation of arrestin-3 C-loop 
A recent crystal structure of the visual arrestin-1-rhodopsin complex revealed a direct 
interaction between the C-loop of arrestin-1 (Fig. 1A, pink) and the receptor [26, 47]. The C-
loop connects two -strands in the C domain of all arrestins, and is found in close proximity 
to the middle-loop in the basal conformation of all arrestins [23, 24, 32, 33]. To test the role of 
this loop in receptor binding, we generated single mutations in the C-loop at three selected 
positions:  Ser246, A248 and Q249. These residues were replaced with residues in 
homologous positions of invertebrate arrestins [13] in the context of the Ala87Val arrestin-3.  
Gln249 is the least conservative position of the C-loop (Fig. 1B). While Gln dominates 
in non-visual arrestins, Tyr and Phe are found at the corresponding place in visual arrestin-1. 
The Gln249His substitution somewhat increased the basal binding to 2AR and D1R, but the 
increase of BRET signal upon isoproterenol or dopamine stimulation were not different from 
WT arrestin-3.   
The replacement of Ala248 with a larger hydrophobic residue Val, yielded enhanced 
receptor binding upon activation in case of two class A receptors out of four tested (Fig. 3): 
β2AR and D2R both bound Ala248Val mutant better than WT arrestin-3 or base mutant 
Ala87Val. However, the basal arrestin-3 binding to these receptors was not affected by 
Ala248 mutation. The Ala248Val substitution reduced arrestin-3 interaction with inactive D1R.  
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Interestingly, neither glutamate nor glutamine substitution of Ser246 in the same loop 
where Ala248 and Gln249 are localized affected the binding to the four receptors tested (Fig. 
3). 
3.3 Middle and C-loop of arrestin-3 participate in rhodopsin binding 
The crystal structure of the rhodopsin-arrestin-1 complex identifies global 
conformational changes in receptor-bound arrestin-1 as compared to basal arrestin-1, 
including an increase in the distance between the middle-loop and C-loop. This particular 
conformational rearrangement forms cleft that allows binding of the second intracellular loop 
of rhodopsin [26]. Arrestin-3 is not a cognate interaction partner of rhodopsin, but can bind to 
P-Rh*, although it yields lower binding than arrestin-1 [16, 19]. To test whether the same 
interaction interface drives non-visual arrestin binding to rhodopsin, we incorporated 
radiolabeled leucine into untagged arrestin-3 mutants [28, 48] and performed in vitro binding 
to rhodopsin [16, 48]. We found that the Lys139Ile mutation of arrestin-3 significantly reduced 
P-Rh* binding, whereas arrestin-3 harboring other substitutions exhibited binding that was 
not statistically different from WT (Fig. 4). Intriguingly, a recent report indicates that when the 
analogous residue in mouse arrestin-1 (Lys 142) is substituted, the conservative Lys142Arg 
and, to a lesser extent, Lys142His mutation enhanced binding to both P-Rh*, and Rh*, 
whereas alanine and glutamine substitutions did not affect the binding [44]. Our test of 
arrestin-3 mutants yielded similar results (Fig. 4). Among C-loop mutations, Ala248Val 
enhanced arrestin-3 binding, whereas the others did not (Fig. 4). 
 
3.4. Agonist-independent receptor recruitment of arrestin-3-Lys139Ile mutant 
 
 Muscarinic acetylcholine receptors display measurable constitutive activity in 
heterologous expression systems [49]. This raises the possibility that the high basal binding 
of arrestin-3-Lys139Ile is due to its preference towards a spontaneously active pool of M2 
receptors. Therefore, we tested whether the mutant binds the truly inactive receptors, by 
incubating cells with atropine, a known inverse agonist of the M2 receptor [49]. We found that 
atropine pretreatment did not decrease the binding of arrestin-3-Lys139Ile, and the agonist-
independent binding of the WT arrestin-3 or the A87V base-mutant were not altered, either 
(Fig. 5). As expected, atropine pretreatment prevented all carbachol-induced BRET changes. 
These data support the notion that the Lys139Ile mutant binds the inactive conformation of 
M2R.  
     As high agonist-independent binding of arrestin-3-Lys139Ile mutant (Fig. 2) is fairly 
unusual, we tested it using co-immunoprecipitation as an independent method (Fig. 6). To 
this end, we transfected HEK293 cells made deficient for both non-visual arrestins using 
CRIPR/Cas9 [30] to exclude endogenous arrestin competition with the same HA-M2R-RLuc8 
and Venus-arrestin-3-Lys139Ile constructs used for BRET (Fig. 2), immunoprecipitated the 
receptor with anti-HA antibody, and blotted for Venus. In these experiments we used WT 
arrestin-3 as a positive control and arrestin-3-KNC that does not bind receptors [22, 25, 29], 
as a negative control (Fig. 5). We found that arrestin-3-Lys139Ile binds M2 muscarinic 
receptors in the absence of agonists, and the addition of saturating agonist 10 µM 
carbamylcholine does not further increase its binding (Fig. 5). In full agreement with BRET 
data (Fig. 2), if anything, the addition of the agonist slightly suppresses the interaction of this 
mutant with M2R, although in neither case this trend rose to statistical significance (Fig. 5).  
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4. Discussion 
 
Arrestins preferentially bind active phosphorylated GPCRs, precluding their coupling 
to G proteins, facilitating receptor internalization, and/or facilitating G protein-independent 
signaling [50-52]. Vertebrates express only four arrestin subtypes [13], as compared to 
hundreds of different GPCRs [11, 12]. Arrestin-1 and arrestin-4 are specialized visual 
proteins, and are expressed at fairly high levels in photoreceptor cells, where they bind 
photopigments [14, 53, 54]. The two non-visual subtypes, arrestin-2 and -3, are ubiquitously 
expressed and bind hundreds of different GPCRs [13, 18, 50, 55-58]. Non-visual arrestins 
also interact with numerous non-receptor signaling proteins [59], orchestrating a second, G 
protein-independent wave of GPCR signaling [13, 60, 61]. 
Arrestin-3 is the most promiscuous of the two non-visual subtypes: it interacts with a 
wide variety of GPCRs [18, 33, 58]. Previously, by manipulating the residues on the receptor-
binding surface that determine receptor specificity of arrestins [20, 21], we constructed 
arrestin-3 mutants with up to 50-fold preference for some GPCR subtypes over others [22]. 
In the first set of point mutants the effects of substitutions on agonist-independent “pre-
docking” and agonist-induced increase in arrestin binding to 2AR, M2R, D1R and D2R 
appeared to correlate [22]. More extensive mutagenesis of the same regions yielded variants 
of arrestin-3 that showed virtually no “pre-docking”, but normally responded to agonist 
challenge of neuropeptide Y receptors Y1 and Y2 [25]. None of the mutations tested affected 
arrestin-3 interactions with D1R and Y1 receptor significantly [22, 25], suggesting that 
additional residues might be involved. The crystal structure of the arrestin-1-rhodopsin 
complex [26] revealed direct contacts between rhodopsin and two loops in the central “crest” 
of the arrestin-1 molecule (Fig. 1A), the middle loop [41] and the C-loop [26]. 
Pre-activating mutations destabilize the basal conformation of arrestin, suggesting 
that fully active arrestin conformation can only be stable in its receptor-bound state. The first 
crystal structure of pre-activated arrestin-1 in complex with a constitutively active rhodopsin 
mutant has recently been solved [26, 47], revealing new aspects of the arrestin-receptor 
interaction. The structure showed that several distinct contact surfaces mediate arrestin-1 
binding to rhodopsin [26]. One of the critical interaction sites in the center of arrestin 
molecule is created by the middle and the C-loop, coming from the N- and C-domain, 
respectively. Receptor binding is accompanied by global conformational changes in arrestin, 
including ~20° rotation between the N- and C-domain [26, 62, 63]. 
The middle loop is highly flexible both in free arrestin-1 [24, 34] and in the rhodopsin 
complex [26]. Intramolecular distance measurements in arrestin-1 revealed large movement 
of the middle loop [46]. Deletions in this element (called “139-loop” in arrestin-1) enhanced 
arrestin-1 binding to phosphorylated, light activated rhodopsin (P-Rh*) and non-preferred 
forms, light-activated unphosphorylated, inactive phosphorylated rhodopsin, and phospho-
opsin [44, 46]. Perturbations in this region also dramatically reduced thermal stability of the 
protein [44] . These results suggest that the presence of this loop contributes to the high 
selectivity of arrestin-1 for P-Rh* and stabilizes the basal conformation. Structural data also 
suggest the existence in the basal state of a salt bridge between Lys142 in the middle-loop 
and Asp72 in the finger loop (residue numbers correspond to bovine arrestin-1), which might 
contribute to the stability of the basal conformation.   
Here we tested nine mutations in the middle and C-loops of arrestin-3 (Figs. 2-4). The 
results are consistent with the hypothesis that these elements directly participate in the 
binding of non-phosphorylated parts of GPCRs, in agreement with the structure of the 
arrestin-1-rhodopsin complex, where these elements directly contact the receptor [26]. 
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Various middle loop and C-loop mutations increase (Lys139Arg, Ala248Val) or decrease 
(Lys139Ile) GPCR binding in receptor-specific manner (Figs. 2-4). Based on the current 
model of arrestin activation [5, 64], arrestin binding to the receptor can be increased via two 
distinct mechanisms: destabilization of the basal conformation [10, 44, 46, 65-67] or 
changing the residues that contact the receptor [37, 68]. The mutations of the first type tend 
to increase the binding to all GPCRs indiscriminately [16, 17]. Since the effects of the 
mutations tested here are receptor subtype-specific (Figs. 2-4), it is likely that targeted 
residues are in the arrestin-receptor interface, similar to previously characterized mutants 
[22, 25].  
However, there is a difference. All earlier constructed mutants with enhanced receptor 
specificity demonstrated lower than WT arrestin-3 binding to some receptors. The specificity 
was achieved by large reduction of binding to some GPCRs with minimal to no reduction of 
the interactions with others [22, 25]. Several mutants tested here demonstrate an increase in 
binding to certain GPCRs: Lys139Ile dramatically enhances the binding to inactive M2R, to 
the level where agonist stimulation of this receptor does not produce any effect (Fig. 2). 
Interestingly, the same mutation reduces arrestin-3 binding to D1 and D2 dopaminergic 
receptors (Figs. 2,4). While none of the previously tested mutations appreciably affected 
arrestin-3 binding to D1R, one mutation in this series, Gln249His, enhanced it, whereas two 
others, Lys139Ile and Ala248Val, decreased it (Figs. 2,3). In fact, Ala248Val selectively 
reduced the binding to D1R, while increasing the binding to rhodopsin, D2R, and 2AR (Figs. 
3,4). Thus, manipulation of these residues, which are likely engaged by the receptor directly, 
yielded arrestin-3 variants where receptor preference was achieved by selective increase in 
the binding to some GPCRs, rather than solely by receptor-specific reduction of the binding 
(Figs. 2,3,7). For the sake of clarity, we presented receptor preference of the biased arrestin 
mutants as radar charts, which show that some point mutations yield 2-5-fold selectivity 
toward certain receptors over others (Fig. 7). Importantly, the magnitude and direction of bias 
is strongly dependent on the activation state of the receptors (Fig. 7). 
Cellular signaling is regulated by a complex network of protein-protein interactions 
[69-71]. The majority of the therapeutically used agents are small molecules, which have 
limited ability to interact with flat or disordered protein elements mediating these interactions 
[72, 73]. Manipulation of these interactions by changing expression levels of proteins 
involved affects every function of proteins in question, not the one function that needs to be 
targeted [74]. Custom-designed signaling proteins can overcome this limitation, and 
selectively enhance or disrupt individual protein-protein interactions [22, 75-77]. Arrestins 
play a role in many critical cellular functions, including cell death and survival [13, 60, 78-80]. 
All of their effects are mediated through direct binding to other proteins, which gives arrestins 
exceptional potential in protein-based therapy [22]. The putative usefulness of an enhanced 
arrestin molecule in compensational gene therapy has already been proven with an 
enhanced form of arrestin-1, which prolonged photoreceptor survival and improved rod 
function in rhodopsin kinase-deficient mice [10]. Non-visual arrestins can be pre-activated by 
homologous mutations [16, 17, 81, 82]. Enhanced versions of non-visual arrestins can 
quench hyperactive GPCRs in all cell types where excessive receptor signaling underlies 
disease state [1, 2]. However, broad receptor specificity of non-visual arrestins does not 
allow specific targeting of the receptor of interest. Our data demonstrate that there are many 
ways of narrowing receptor specificity of even the most promiscuous non-visual subtype, 
arrestin-3, paving the way to the construction of arrestin mutants with therapeutic potential.  
 
5. Conclusions 
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Here we show that the middle-loop (called 139-loop in arrestin-1) and the C-loop are 
important parts of the receptor-binding surface of arrestin-3, and that the manipulation of 
these segments yields subtype-selective changes of non-visual arrestin interactions with 
different GPCRs. One of the introduced mutations, Lys139Ile, has resulted in high-affinity 
basal (agonist-independent) binding of arrestin-3 to M2 muscarinic receptor, while reducing 
the agonist-induced interaction with D2 dopamine receptor. Subtype-specific increase in 
receptor binding described here can enhance the specificity of non-visual arrestins in a 
different way than in previous studies, where a decrease of arrestin-3 binding to certain 
receptor subtypes enhanced the receptor specificity of arrestin-3.  
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Figure legends: 
Fig. 1. Structure and sequence of the middle and C-loops of arrestins. 
A. Crystal structure of rhodopsin-bound arrestin-1 (Protein Data Bank entry 4ZWJ [26]). The 
middle and C-loops are shown in blue and pink, respectively. Residues mutated in this study 
are shown as CPK. B. Multiple sequence alignment of arrestin-1 (Arr1), arrestin-3 (Arr3) and 
arrestin homologs (Arr) from invertebrate species. Residues mutated in this study are 
highlighted. Bar graph under the alignment shows the extent of residue conservation at each 
position.  
 
Fig. 2. Basal and agonist-induced binding of Lys139 mutants to GPCRs. 
A. Basal (agonist-independent) association of the indicated luciferase-tagged receptor and 
wild type or mutant Venus-Arrestin-3 in COS-7 cells at 10 minutes of vehicle treatment. 
Nonspecific (bystander) BRET was measured using non-receptor-binding arrestin-3 mutant 
(Arrestin3-KNC[22, 29]). Net BRET ratio was calculated by subtracting non-specific BRET 
from the raw BRET data in each experiment. B. The agonist-induced arrestin-3 recruitment 
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to indicated receptors. The BRET change (ΔBRET) was determined by the difference 
between the BRET ratio between ligand and vehicle treated cells (nonspecific BRET was 
subtracted from both). Means ± S.E. of at least three independent experiments are shown. 
Each experiment was performed in quadruplicate. Statistical significance was determined by 
one-way ANOVA, followed by Dunnett's post-hoc test: *, p < 0.05; **, p < 0.01; ***, p < 0.001, 
as compared with A87V base mutant binding to each receptor.  
 
Fig. 3. The effect of C-loop mutations on basal and agonist-induced receptor binding. 
A. Basal BRET (net BRET ratio) and B. agonist-induced BRET change (delta BRET) 
between indicated luciferase-tagged receptors and Venus-tagged arrestin-3 C-loop mutants 
was calculated, as described in the legend to Fig. 2. The cells were stimulated for 10 minutes 
with the appropriate agonist. BRET ratio obtained with negative control (arrestin-3 KNC [25, 
83]) was subtracted. Means ± S.E. of at least three independent experiments are shown. 
Each experiment was performed in quadruplicate. Statistical significance was determined by 
one-way ANOVA: *, p < 0.05; **, p < 0.01; ***, p < 0.001, as compared with A87V base 
mutant binding to each receptor.  
 
Fig. 4. Direct binding of arrestin-3 mutants to light-activated phosphorylated 
rhodopsin. 
WT and mutant forms of arrestin3 produced in cell-free translation in the presence of 
radiolabeled leucine (2 nM) were incubated with 0.3 g of light-activated phosphorylated 
rhodopsin (P-Rh*) for 5 min at 37 °C. Free and rhodopsin-bound arrestins were separated by 
gel filtration on 2-ml Sepharose 2B-CL columns. The amount of bound arrestin eluting with 
rhodopsin-containing membranes was quantified by scintillation counting. Non-specific 
binding (in the absence of rhodopsin) was subtracted. Means ± S.D. of three independent 
experiments performed in duplicate are shown. The data were analyzed by one-way ANOVA 
with arrestin type as the main factor, followed by Dunnett's post-hoc test. 
 
Fig. 5. Lys139Ile mutant binds inactive M2R. COS-7 cells co-expressing M2R-RLuc8 and 
indicated form of Venus-arrestin-3. Cells were pretreated for 5 minutes with vehicle or 10 µM 
inverse agonist atropine [49], and stimulated with carbamylcholine as in Fig. 2. Raw BRET 
ratios are shown.  Basal arrestin-3 binding was not altered by atropine treatment. *,p<0.05 
(vs. vehicle control), analyzed with one-way repeated measures ANOVA, followed by 
Dunnett post-hoc test. Atropine prevented the effects of carbachol. #,p<0.05 (significant 
interaction between the two treatments), analyzed with two-way repeated measures ANOVA, 
followed by Bonferroni post-hoc test. 
 
 
 
Fig. 6. Co-immunoprecipitation of Venus-arrestin constructs with M2R. HEK arrestin-2/3 
KO cells [30] were co-transfected with Venus-arrestin constructs and HA-M2R-RLuc8. After 
48 h, the cells were incubated in either serum-free media alone, or serum-free media with 10 
µM carbamylcholine for 15 min. The cells were lysed in IP buffer (50 mM Tris-HCl pH 7.5, 2 
mM EDTA, 250 mM NaCl, 10% glycerol, 0.5% NP-40, 20 mM NaF, and 1mM NaVO3) and 
the supernatant was cleared by centrifugation at max speed for 15 min, then pre-cleared with 
protein G agarose. The supernatant was immunoprecipitated using a rat HA antibody against 
HA-M2R-Rluc8. The input (IB) and immunoprecipitated material (IP) were subjected to 
Western blotting to detect HA and GFP, as indicated. The GFP blot of the 
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immunoprecipitated samples was analyzed using Versadoc. The results were statistically 
analyzed using one-way ANOVA followed by Dunnett’s post-hoc test. The difference with 
KNC is shown (*, p<0.05, n=3). The effect of agonist treatment on Venus-arrestin-3 (K139I) 
was not statistically significant (n.s).  
 
Fig. 7. Receptor selectivity of arrestin-3 mutants. 
Each receptor pair is provided a radially arranged axis that starts from the centre. The 
relative binding of each arrestin-3 mutant was plotted along all axes, and the connected 
values create a polygon. The binding ratio of wild type arrestin-3 was set at 1 for each 
receptor pair. If the relative binding is greater than 1, the indicated arrestin has a preference 
for the first member of the receptor pair (receptor1/receptor2). Panel A shows the basal 
arrestin interactions. The green regular hexagon indicates wild type arrestin. Only those 
mutants are highlighted that have at least a 1.5-fold bias against one receptor. Panel B 
shows the selectivity of the arrestin3 mutants after ligand treatment. 
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